Published in Nat Genet on May 01, 1997
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology (2014) 1.78
Precursors to pancreatic cancer. Gastroenterol Clin North Am (2007) 1.75
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol (2015) 1.73
BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol (2000) 1.72
Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology (2011) 1.70
High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res (2013) 1.63
Update on familial pancreatic cancer. Adv Surg (2010) 1.54
Detecting early pancreatic cancer: problems and prospects. Semin Oncol (2007) 1.54
Genetic alterations in pancreatic carcinoma. Mol Cancer (2003) 1.43
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol (2008) 1.36
Hereditary pancreatic cancer. Gastroenterology (2010) 1.31
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
Familial pancreatic cancer--current knowledge. Nat Rev Gastroenterol Hepatol (2012) 1.27
Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet (1999) 1.26
Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut (2006) 1.19
Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res (2012) 1.09
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer (2014) 1.08
Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int (2011) 1.03
Pancreatic cancer screening. Gastroenterol Clin North Am (2012) 1.02
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer (2001) 1.01
Hereditary breast cancer in Jews. Fam Cancer (2004) 0.99
Inherited predisposition to pancreatic cancer. Gut (2001) 0.97
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet (2008) 0.95
Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers. Cancer (2011) 0.93
BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer (2000) 0.91
Screening and early detection of pancreatic cancer in high risk population. World J Gastroenterol (2014) 0.88
Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer (2010) 0.88
Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Fam Cancer (2015) 0.87
Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res (2008) 0.87
Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn (2008) 0.86
Familial pancreatic cancer: genetic advances. Genes Dev (2014) 0.86
Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer (2008) 0.84
Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut (2002) 0.83
Genetics and pathology of pancreatic cancer. HPB (Oxford) (2006) 0.82
Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med (2013) 0.82
Familial pancreatic cancer. Fam Cancer (2004) 0.81
Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns (2008) 0.77
Pathogenic Mutations in Cancer-Predisposing Genes: A Survey of 300 Patients with Whole-Genome Sequencing and Lifetime Electronic Health Records. PLoS One (2016) 0.76
Elevated DNA damage response in pancreatic cancer. Histochem Cell Biol (2014) 0.76
Restoration of CAPAN-1 cells with functional BRCA2 provides insight into the DNA repair activity of individuals who are heterozygous for BRCA2 mutations. Cancer Genet Cytogenet (2008) 0.76
Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b. Front Genet (2016) 0.75
Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptormediated apoptosis. Oncotarget (2016) 0.75
Pancreatic Cancer Screening. Curr Treat Options Gastroenterol (2017) 0.75
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Observational study of effect of patient centredness and positive approach on outcomes of general practice consultations. BMJ (2001) 8.76
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med (2000) 8.68
Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA (1991) 7.35
Performance indicators for primary care groups: an evidence based approach. BMJ (1998) 6.97
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
Preferences of patients for patient centred approach to consultation in primary care: observational study. BMJ (2001) 6.17
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
The chorio-allantoic membrane of the developing chick as a medium for the cultivation and histopathologic study of pathogenic fungi. Am J Pathol (1941) 4.64
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24
Definition and classification of negative outcomes in solid organ transplantation. Application in liver transplantation. Ann Surg (1994) 4.24
23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet (2000) 4.23
Gain of function mutations in p53. Nat Genet (1993) 4.19
Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ (2001) 4.18
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell (1996) 4.13
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 4.10
The Chorioallantoic Membrane of Chick Embryos and Its Response to Inoculation with Some Mycobacteria. Am J Pathol (1942) 4.02
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg (1996) 3.76
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics (2000) 3.48
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 3.43
Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med (1999) 3.38
The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol Cell Biol (1986) 3.36
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet (2004) 3.03
A study of clients returning for counseling after HIV testing: implications for improving rates of return. Public Health Rep (1993) 3.01
Subepithelial connective tissue graft technique for root coverage. J Periodontol (1985) 3.01
Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet (2004) 2.95
Multiple adenovirus serotypes use alpha v integrins for infection. J Virol (1994) 2.86
Mating Control by Gene Arrangements in DROSOPHILA PSEUDOOBSCURA. Genetics (1966) 2.80
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77
Nutritional assessment: a comparison of clinical judgement and objective measurements. N Engl J Med (1982) 2.74
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Relationship between trauma center volume and outcomes. JAMA (2001) 2.56
Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med (2001) 2.51
MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet (1995) 2.49
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol (2002) 2.46
CAISSON DISEASE WITH SPECIAL REFERENCE TO THE BONES AND JOINTS: REPORT OF TWO CASES. Ann Surg (1940) 2.44
Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol (2001) 2.41
Multidisciplinary cancer conferences: a systematic review and development of practice standards. Eur J Cancer (2007) 2.41
Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med (2000) 2.39
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
Percutaneous fine-needle aspiration biopsy. I. Its value to clinical practice. Cancer (1980) 2.36
Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health Technol Assess (2009) 2.36
Randomised controlled trial of self management leaflets and booklets for minor illness provided by post. BMJ (2001) 2.35
GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron (1998) 2.34
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer (1996) 2.33
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
Overnight calls in primary care: randomised controlled trial of management using nurse telephone consultation. BMJ (1999) 2.32
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Tuberculosis among foreign-born persons in the United States, 1993-1998. JAMA (2000) 2.31
Antidepressant medication use and breast cancer risk. Am J Epidemiol (2000) 2.29
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2008) 2.27
Validation study of a diary for use in acute lower respiratory tract infection. Fam Pract (2001) 2.24
Importance of lead selection in QT interval measurement. Am J Cardiol (1988) 2.23
Total parenteral nutrition at home: studies in patients surviving 4 months to 5 years. Gastroenterology (1976) 2.21
Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Edinburgh Heterosexual Transmission Study Group. Lancet (1996) 2.20
Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. Proc Natl Acad Sci U S A (1991) 2.19
Clinical governance in primary care groups: the feasibility of deriving evidence-based performance indicators. Qual Health Care (2000) 2.16
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet (1997) 2.15
Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell (1994) 2.15
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet (1998) 2.12
Allelotype of pancreatic adenocarcinoma. Cancer Res (1994) 2.11
Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. Proc Natl Acad Sci U S A (1998) 2.09
Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet (2012) 2.06
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer (1984) 2.05
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol (2007) 2.03
Relation between hospital surgical volume and outcome for pancreatic resection for neoplasm in a publicly funded health care system. CMAJ (1999) 2.03
Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. Am J Pathol (1999) 2.02
BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genet (2014) 2.02
A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol (2001) 2.01
Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res (2001) 2.00
Cost analysis of nurse telephone consultation in out of hours primary care: evidence from a randomised controlled trial. BMJ (2000) 1.99
On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet (1997) 1.94
Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J Exp Med (1996) 1.93
Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature (2000) 1.93
Bending overload and implant fracture: a retrospective clinical analysis. Int J Oral Maxillofac Implants (1995) 1.92
DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med (1993) 1.91
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88
Total parenteral nutrition at home for 23 months, without complication, and with good rehabilitation. A study of technical and metabolic features. Gastroenterology (1973) 1.87
Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol (1999) 1.85
Periampullary tumors: which ones should be resected? Am J Surg (1985) 1.85
Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res (1994) 1.85
Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med (1977) 1.85
Changing causes of mortality in patients with familial adenomatous polyposis. Dis Colon Rectum (1996) 1.82
POLYAMINES, RNA SYNTHESIS, AND STREPTOMYCIN LETHALITY IN A RELAXED MUTANT OF E. coli STRAIN 15 TAU. Proc Natl Acad Sci U S A (1967) 1.82
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81